Biosynth expands Berlin site with a commercial bioconjugation suite

Biosynth opens expanded GMP bioconjugation facility in Germany

The new facility is claimed to enhance Biosynth’s ability to manufacture GMP bioconjugates, supporting the production of intermediates and active pharmaceutical ingredients from early clinical stages till late-phase The post Biosynth opens expanded GMP bioconjugation facility in Germany appeared first on Pharmaceutical Business review.

Biosynth expands Berlin site with a commercial bioconjugation suite

Biosynth, a developer and supplier of critical raw materials and services for life sciences and diagnostics, has announced the opening of its expanded GMP bioconjugation facility at its existing Berlin site.